Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial

BEVERLY, Mass.–(BUSINESS WIRE)– #VIE–Akston announced topline results: Phase II COVID booster trial found 93% of previously vaccinated subjects had increased neutralizing antibody titers.
Click here to view original post